---
title: "Boule Diagnostics AGM Retains Earnings, Renews Board Mandates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286293671.md"
description: "Boule Diagnostics AB's 2026 AGM approved the 2025 financial statements, decided to retain earnings without a dividend, and granted discharge from liability to the board and CEO. The existing board structure was reaffirmed, reappointing all five directors, including chairman Torben Jørgensen. Shareholders renewed key authorizations for issuing new shares and managing the company's own shares, enhancing Boule's financial flexibility for future capital raising and strategic options. Boule Diagnostics operates in decentralized hematology and diagnostic solutions globally, with a market cap of SEK125.4M."
datetime: "2026-05-13T16:34:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286293671.md)
  - [en](https://longbridge.com/en/news/286293671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286293671.md)
---

# Boule Diagnostics AGM Retains Earnings, Renews Board Mandates

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Boule Diagnostics AB ( (SE:BOUL) ) just unveiled an announcement.

Boule Diagnostics’ 2026 annual general meeting approved the 2025 financial statements, decided to retain earnings with no dividend, and granted discharge from liability to the board and CEO. The meeting reaffirmed the existing board structure and compensation levels, reappointing all five directors, including chairman Torben Jørgensen, and re-electing Öhrlings PriceWaterhouseCoopers AB as auditor.

Shareholders also backed the remuneration report and renewed key authorizations that give the board flexibility to issue new shares, warrants or convertibles, and to acquire or transfer the company’s own shares. These mandates strengthen Boule’s financial and strategic optionality, supporting potential future capital raising, balance-sheet management or share-based measures without immediate changes to its governance or payout policy.

**More about Boule Diagnostics AB**

Boule Diagnostics AB is a Sweden-based global diagnostics company operating through two segments, Diagnostics and OEM CDS. It provides decentralized near-patient hematology and related diagnostic solutions for human and veterinary use, and supplies reagents, blood controls and calibrators to diagnostic companies worldwide, with operations in several countries and distribution in over 100 markets.

**Average Trading Volume:** 46,948

**Technical Sentiment Signal:** Sell

**Current Market Cap:** SEK125.4M

For a thorough assessment of BOUL stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [512170.CN](https://longbridge.com/en/quote/512170.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal](https://longbridge.com/en/news/286808399.md)
- [IceCure ProSense kidney cancer trial shows 89.4% recurrence-free rate at 4 years](https://longbridge.com/en/news/286912762.md)
- [Immunovia AGM Backs New Share Issue Mandate and Major Option Program](https://longbridge.com/en/news/286249918.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)